|
|
|
 |
 |
NEOVACS
is developing a novel immunotherapy strategy to elicit human
polyclonal antibodies (Abs) against deleterious stromal
factors responsible for the microenvironmental disorders
in pathologic tissues of chronic
diseases, such as AIDS,
cancer and autoimmunity.
|
| |
|
| |
|
| |
|
|
NEOVACS' approach consists in triggering, by an active immunization,
high titer antibodies neutralizing the deleterious stromal
factors and counteracting their effects. This novel immunotherapy
strategy can be used on its own, or can be combined with other
therapies including conventional immunotherapies or chemotherapy.
NEOVACS' immunotherapies, issued from licensed concepts and
procedures to produce immunogenic heterocomplexes, belong
to 2 families of products: TOXOIDS
and KINOIDS.
|
| |
|
|
| |
Passive
Ab therapy |
Neovacs
active Ab therapy |
| |
| Current
active principle |
Humanized/chimaeric Abs |
Cytokine derivatives |
| Medical
use |
Therapeutic
|
Therapeutic
|
| Abs
to pathogenic Ag |
Monoclonal
|
Polyclonal |
| Serum
neutralizing Ab titers at peak |
High |
High |
| Specific
cellular response |
None |
None |
| Effective
immunity |
Immediate |
3-4 weeks |
| Decline
of immunity |
2-3 weeks |
3-6 months |
| Booster
injections |
2 to 3 per month |
2
to 4 per year |
| Anti-Ab
response |
Following repeated injections* |
None |
| Risk
of relapse |
Following repeated injections* |
None |
| Patient's
compliance |
Cumbersome
|
Well-tolerated |
| Cost
|
High |
Low |
|
| Characteristics
of passive and active immunization procedures relevant
to their therapeutic use.
*Specific anti-idiotypic Abs to passively administered
anti-cytokine Abs may be induced by repeated booster
injections.
|
|
| |
|
| |
 |
|
|
|
